CN1410075A - Application of fur seal oil in preparation of medicine for treating lipometabolism disorder (high blood fat) - Google Patents
Application of fur seal oil in preparation of medicine for treating lipometabolism disorder (high blood fat) Download PDFInfo
- Publication number
- CN1410075A CN1410075A CN01135519A CN01135519A CN1410075A CN 1410075 A CN1410075 A CN 1410075A CN 01135519 A CN01135519 A CN 01135519A CN 01135519 A CN01135519 A CN 01135519A CN 1410075 A CN1410075 A CN 1410075A
- Authority
- CN
- China
- Prior art keywords
- medicine
- application
- phocae vitulinae
- adeps phocae
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
An application of ursine seal's fat to preparing medicines to treat fat metabolism disorder (hyperlipomia) is disclosed. Its advantage is high curative effect on lowering the level of serum cholesterol and triglyceride and increasing that of HDL.
Description
Technical field
What the present invention relates to is that specifically, what the present invention relates to is the application of Adeps Phocae vitulinae being controlled mammal and people's treatment disorders of lipid metabolism (hyperlipidemia) medicine as preparation with the application of Adeps Phocae vitulinae as preparation treatment disorders of lipid metabolism (hyperlipidemia) medicine.
Background technology
As everyone knows, patient's quantity of diseases such as diabetes, hepatopathy, prostate, hyperlipidemia is very huge, and in the practical application, has special positive effect and the medicine of almost being free from side effects is difficult to confirm.
It has been generally acknowledged that patient's quantity that Eskimos and Japanese coastal fisherman suffer from this type of disease is significantly lower than general crowd, research worker believe this phenomenon and eat the fur seal meat that is rich in unsaturated fatty acid with them, oil is relevant.
But, do not have concrete zoopery or clinical effectiveness to be proved so far.
Described in the present invention fur seal typically refers to a kind of mammal of life Newfoundland, North Atlantic Region, the arctic, in their body fats unsaturated fatty acid content up to 25%, and its molecular structure and the intravital fatty acid molecule structural similarity of people.
Adeps Phocae vitulinae of the present invention (claiming seal oil again) is meant that the subcutaneous fat by above-mentioned fur seal refines the all-natural product that forms.
Result of study shows, containing in the body of a large amount of needed by human in the Adeps Phocae vitulinae can not synthetic voluntarily ω-3 be long carbochain polyene unsaturated fatty acid and a spot of Squalene (SPUALENE).
Summary of the invention
The object of the present invention is to provide a kind of with the application of Adeps Phocae vitulinae as preparation treatment disorders of lipid metabolism (hyperlipidemia) medicine.
The Adeps Phocae vitulinae that pharmacological experiment of the present invention adopts is to extract the little yellow oily liquid that forms in the fur seal body, provide in soft capsule (0.5g/ grain) mode by Canadian Atlantic Ocean wholesome food company limited, lot number is 11656, and described Adeps Phocae vitulinae adopts room temperature preservation at laboratory.
For the further composition and the content of clear and definite above-mentioned Adeps Phocae vitulinae, below the composition of Adeps Phocae vitulinae used in the present invention is analyzed and confirmed.
Prior art shows that the ω that extracts-3 is that the chemical main composition of polyene unsaturated fatty acid is EPA, DHA and DPA from Adeps Phocae vitulinae, wherein:
EPA is meant eicosapentaenoic acid;
DPA is meant clupanodonic acid;
DHA is meant docosahexenoic acid;
Research worker of the present invention is carried out the mensuration of projects such as ultra-violet absorption spectrum, infrared absorption spectroscopy, gas chromatogram, gas chromatography-mass spectrometry chromatogram to the Adeps Phocae vitulinae of above-mentioned acquisition, and the chemical constitution of described sample is confirmed, and is specific as follows:
The Adeps Phocae vitulinae test result of samples that the present invention adopts is:
(1) ultra-violet absorption spectrum
With chloroform (analytical pure) sample is made into and carries out the long UV scanning of all-wave behind the 5.9mg/ml solution, the model of employed instrument is U-3210spectrophotometer (Japan manufacturing); Referring to accompanying drawing 1, its result shows that sample has absorption maximum at the 249.8nm place, can prove and contain a large amount of unsaturated bonds in the sample;
(2) infrared absorption spectroscopy
Referring to accompanying drawing 2, its result shows, at 3010cm
-1And 1745cm
-1The strong absorption at place be respectively unsaturated=C-H and＞characteristic absorption of C=O stretching vibration; 1655cm
-1The weak absorption at place meets the stretching vibration characteristic absorption (1665-1635cm of cis-double bonds (R1-C=C-R2)
-1, trans is 1675-1665cm
-1), H/ H722cm
-1The absworption peak at place meets the characteristic absorption (730-665cm of cis-double bonds=C-H bending vibration
-1, trans is 980-960cm
-1).
Comprehensive infrared and ultraviolet spectral analysis can be thought to be mainly the cis non-conjugated fatty acid in the sample.
(3) gas chromatogram
In this detection, the accepted standard product are provided by SIGMA company, are respectively:
Cis-5,8,11,14,17-EICOSAPENTAENOIC ACID METHYL ESTER, methyl eicosapentaenoic acid;
Cis-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER, docosahexaenoic acid ethyl;
Cis-7,10,13,16,19-DOCOSAPENTAENOIC ACID METHYL ESTER, clupanodonic acid methyl ester;
Sample is the Adeps Phocae vitulinae of above-mentioned acquisition, analyzing fatty acid with the GC method need be with its ethyl esterization in order to gasification, specifically be to get described sample 80 μ l, the NaOH-ethanol liquid 1ml that adds 0.5ml/l, fill N2, jump a queue, jolting adds boron trifluoride ethanol liquid 1.5ml to little oil droplet complete obiteration in 50 degrees centigrade of water-baths.Mix homogeneously is put 5min in 50 degree water-baths, take out cooling, and adding normal heptane 1ml, saturated NaCl is the 2ml mix homogeneously, layering.Get upper strata liquid in another test tube, add a small amount of anhydrous NA2SO4, fill N2, place in 4 degree and treat that GC analyzes.
Employed instrument is HP6890;
GC conditions: glass filled post 2m * 3mm, 10%DEGS pickling, 101 white carriers, carrier gas N2, flow velocity 25ml/min, detector FID, column temperature 180 degree, vaporizer 210 degree, detector 270 degree, sample size 1ul.
With standard substance normal hexane standardize solution, be configured to 2.5mg/ml solution, precision is measured 1ul and is carried out the gas phase assay, and same method is measured sample, and the result is that the retention time of sample and reference substance is consistent.
Can be referring to accompanying drawing 3-7.
(4) gas-matter coupling method
The instrument that adopts is a U.S. Trace 2000GC/Trace MS type gas chromatograph-mass spectrometer, and all reagent are analytical pure.
Experiment condition is:
GC conditions: the PEG-20M glass capillary column (2m * 0.32mm); Column temperature 40 degree keep 1min, are warming up to 200 degree with 10 degree/min, keep 5min, are warming up to 210 degree with 30 degree/min again, keep 2min; Press 3.0kpa before the carrier gas N2, post, split ratio 1: 30, injector temperature 250 degree; Ion source temperature 250 degree, ionization voltage 70Ev, mass scanning scope 350AmU.S-1; Sample size 1ml.
Through mass spectrogram analysis, determine that the molecular weight of sample and standard substance conforms to.
So far, molecular weight, composition, the content and structure of of the Adeps Phocae vitulinae that the present invention is adopted have obtained confirming.
Experimental example one
This experimental example is to adopt high lipid food to cause the effect of rat disorders of lipid metabolism model testing Adeps Phocae vitulinae of the present invention to the rat disorders of lipid metabolism, pharmacodynamic action to Adeps Phocae vitulinae two weeks of continuous irrigation stomach under 2.2ml/KG dosage is observed, found that, this medicine can make rat blood serum T-CHOL (TC) and triglyceride (TG) level obviously reduce, the HDL level obviously raises, the LDL+VLDL level obviously descends, make that cholesterol levels obviously descends in the hepatic tissue, illustrate that this medicine has tangible blood fat reducing and subtracts the effect of liver fat.
Test material:
(1) Adeps Phocae vitulinae is to extract the little yellow oily liquid that forms in the fur seal body, and the Atlantic Ocean, mountain food company produces, and this laboratory room temperature preservation press the 150g body weight and irritated stomach 1.2ml (high dose use stock solution) or 1ml (in, low dosage use dilute liquid medicine) during test.
(2) positive control drug is zhibituo (0.35g/ levies sheet) that 1.05g.Kg irritates stomach, and 1ml/ is only. lot number 20001024, Chengdu Diao 9 Wang pharmaceutical factory.
(3) high lipid food: 4% cholesterol+10% Adeps Sus domestica+0.2% propylthiouracil+86% mixed fodder; Wherein: cholesterol (plain edition) is by Beijing Olympic star's biotechnology Limited Liability company limited production and sales; Propylthiouracil provides (lot number is 990504) by morning sunlight pharmaceutical factory of The 2nd Army Medical College; Olive oil provides (lot number is 980428) by Beijing fragrant grass pharmaceutical ﹠ chemicall research development corporation
(4) experimental animal is a cleaning level wister rat, body weight 140-160g, and the animal quality certification number: the capital is moving is betrothed to (2000) No. 012, and the Nat'l Pharmaceutical ﹠ Biological Products Control Institute experimental center provides.Observed two days before the experiment, choosing is healthy, active animal is used for test.
Method: get healthy rat, by the body weight random packet, 8 every group
I. blank group: oral fresh water 1ml/ only;
Ii. agent matched group: oral olive oil 1ml/ only;
Iii. model control group: oral olive oil 1ml/ only;
Iv. positive medicine matched group: zhibituo 1.05g/Kg, oral 1ml/ are only;
V. Adeps Phocae vitulinae high dose group: 8.6ml/Kg, oral 1.2ml/ are only;
Vi. dosage group: 4.3ml/Kg in the Adeps Phocae vitulinae, oral 1ml/ is (using dilute liquid medicine) only;
Vii. Adeps Phocae vitulinae high dose group: 2.2ml/Kg, oral 1ml/ is (using dilute liquid medicine) only;
(2)-(7) group gives high lipid food, every day the jar stomach once, in continuous two weeks, the last administration is after one hour, blood lipid level (TC, TL, HDL and LDL+VLDL) is surveyed in the eye socket blood sampling, gets liver and surveys T-CHOL (TC) in the hepatic tissue.
The result: Adeps Phocae vitulinae 4.3ml/Kg-8.6ml/Kg is oral, can obviously reduce rat blood serum cholesterol (TC) level, triglyceride (TG) level, the LDL+VLDL level, rising HDL level, and can obviously reduce cholesterol levels in the hepatic tissue, specifically as seen see Table 1.
Table 1
X ± S compares with model group:
*P＜0.05
*P＜0.01
| Group dosage number of animals TC TG TG LDL+VLDL HDL hepatic tissue cholesterol (g/kg) (only) is (mM/L) (mM/L) (mM/L) (uM/g weight in wet base) (mM/L) |
| ???1?????????????????8????????4.21±2.3???0.5±0.1???0.42±0.2??0.45±0.1??23.64±10.5 ???2?????????????????8????????11.32±3.1??1.1±0.4???0.84±0.1??0.61±0.28?68.88±8.25 ???3?????????????????8????????12.52±4.2??1.3±0.2???0.82±0.3??0.59±0.21?64.84±7.3 |
| 4??????1.05???8?????8.12±2.1 **????0.53±0.1 **?????0.5±0.1 **???0.89±0.35 **???32.64±8.2 **5??????8.6????8?????8.89±2.3 **????0.67±0.2 **?????0.6±0.2 **???0.91±0.42 **???44.28±6.8 **6??????4.3????8?????9.85±3.4 *?????0.8±0.3 *??????0.72±0.3 *???0.78±0.21 *????58.24±5.6 *7??????2.2????8?????10.84±3.2??????1.2±0.45????????0.81±0.2?????0.6±0.1????????65.32±4.5 |
Experimental example two
This experimental example is to adopt high lipid food to cause the effect of rabbit disorders of lipid metabolism model testing Adeps Phocae vitulinae of the present invention to the rabbit disorders of lipid metabolism, at Adeps Phocae vitulinae is under the dosage of 1.1ml/kg-4.5ml/kg, the pharmacodynamic action in two weeks of continuous irrigation stomach is observed, found that, this medicine can make rabbit anteserum T-CHOL (TC) and triglyceride (TG) level obviously reduce, the HDL level obviously raises, the LDL+VLDL level obviously descends, make that cholesterol levels obviously descends in the hepatic tissue, illustrate that this medicine has tangible blood fat reducing and alleviates the effect of liver fat.
Employed test material is as follows in this experimental example:
(1) Adeps Phocae vitulinae, for extracting the glib shape liquid of little yellow that forms in the fur seal body, the Atlantic Ocean, mountain food company produces, and this laboratory room temperature preservation press the 2Kg body weight and irritated stomach 9ml (high dose use stock solution) or 6ml (in, low dosage use dilute liquid medicine) during test.
(2) positive control drug is zhibituo (0.35g/ sheet) that 0.53g/Kg irritates stomach, and 6ml/ only.Lot number 20001024, Chengdu Diao 9 Wang pharmaceutical factory.
(3) high lipid food: the 4% cholesterol+10% Adeps Sus domestica+phonetic shallow lake of 0.2% propylthio oxygen+86% mixed fodder, wherein, cholesterol (plain edition) is provided by Beijing Olympic star's biotechnology Limited Liability company limited; Propylthiouracil provides (lot number is 990504) by morning sunlight pharmaceutical factory of The 2nd Army Medical College; Olive oil provides (lot number is 980428) by Beijing fragrant grass pharmaceutical ﹠ chemicall research development corporation;
(4) experimental animal is a cleaning level rabbit, body weight 2-2.5Kg, and the animal quality certification number: the capital is moving is betrothed to (2000) No. 012, and the Nat'l Pharmaceutical ﹠ Biological Products Control Institute experimental center provides.Observed two days before the experiment, choosing is healthy, active animal is used for test.
Method: get healthy rabbits, by the body weight random packet, 5 every group
(1) blank group: oral fresh water 6ml/ only
(2) solvent control group: oral olive oil 6ml/ only
(3) model control group: oral olive oil 6ml/ only
(4) positive medicine matched group: the oral 6ml/ of zhibituo 0.53/Kg only
(5) Adeps Phocae vitulinae high dose group: 4.5ml/Kgml
(6) the oral 6ml/ of dosage group: 2.2ml/Kg (using dilute liquid medicine) in the Adeps Phocae vitulinae
(7) the oral 6ml/ of dosage group: 1.1ml/Kg (using dilute liquid medicine) in the Adeps Phocae vitulinae
(2)-(7) group gives high lipid food, irritates stomach every day once, and in continuous two weeks, time administration is not after 1 hour, and blood lipid level (TC, T1, HDL and LDL+VLDL) is surveyed in the heart blood sampling, gets liver and surveys T-CHOL (TC) in the hepatic tissue.
The result: Adeps Phocae vitulinae 2.2ml/Kg-4.5ml/Kg is oral, can obviously reduce the rabbit anteserum cholesterol levels, triglyceride (TG) level, and rising HDL level, and can obviously reduce cholesterol levels in the hepatic tissue.See
Table 2
| Group dosage number of animals TC TG LDL+VLDL HDL hepatic tissue cholesterol (g/kg) (only) is (mM/L) (mM/L) (mM/L) (uM/g weight in wet base) (mM/L) |
| ?1?????????????????5????4.8±1.3?????0.54±0.1????0.41±0.2????0.47±0.1?????25.64±8.8 ?2?????????????????5????10.89±2.3???1.25±0.3????0.83±0.15???0.59±0.14????67.83±7.28 ?3?????????????????5????11.53±3.8???1.29±0.2????0.9±0.2?????0.54±0.19????66.53±6.7 ?4??????0.53???????5????7.8±2.9 **??0.62±0.1 **?0.52±0.1 **?0.85±0.28 **?29.8±7.8 **?5??????4.5????????5????7.92±3.2 **?0.72±0.2 **?0.63±???????????????0.84±0.21 **?33.8±5.4 **??????????????????????????????????????????????????0.18 **?6??????2.2????????5????8.3±2.8 *???0.93±0.3 *??0.72±0.2 *?0.71±0.32 *??56.92±4.8 *?7??????1.1????????5????9.92±3.6????1.18±0.45???0.82±0.4????0.58±0.1?????65.32±4.5 |
X ± S compares with model group:
*P＜0.05
*P＜0.01
More than experiment shows that Adeps Phocae vitulinae has the effect of good curing disorders of lipid metabolism (hyperlipidemia).
Description of drawings
Below be description of drawings of the present invention,, can more be expressly understood the present invention by description of drawings and in conjunction with above-mentioned specific descriptions, specific as follows:
Accompanying drawing 1 is the uv absorption spectrogram of Adeps Phocae vitulinae of the present invention;
Accompanying drawing 2 is infrared absorption spectras of Adeps Phocae vitulinae of the present invention;
Accompanying drawing 3-5 is the gas chromatogram of the standard substance of the EPA methyl ester that uses among the present invention, DHA ethyl ester, DPA methyl ester;
Accompanying drawing 6-7 is the gas chromatogram of Adeps Phocae vitulinae of the present invention.
Claims (3)
1, a kind of Main Ingredients and Appearance is the application of the Adeps Phocae vitulinae of eicosapentaenoic acid (EPA), clupanodonic acid (DPA) and docosahexenoic acid (DHA) as preparation treatment disorders of lipid metabolism (hyperlipidemia) medicine.
2, application according to claim 1 is characterized in that the oral dose of the preferred 2.2-8.6ml/kg of described application.
3, application according to claim 1 and 2 is characterized in that the more preferably oral dose of 4.3-8.6ml/kg of described application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011355190A CN1197564C (en) | 2001-09-30 | 2001-09-30 | Application of fur seal oil in preparation of medicine for treating lipometabolism disorder (high blood fat) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011355190A CN1197564C (en) | 2001-09-30 | 2001-09-30 | Application of fur seal oil in preparation of medicine for treating lipometabolism disorder (high blood fat) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1410075A true CN1410075A (en) | 2003-04-16 |
| CN1197564C CN1197564C (en) | 2005-04-20 |
Family
ID=4673174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011355190A Expired - Fee Related CN1197564C (en) | 2001-09-30 | 2001-09-30 | Application of fur seal oil in preparation of medicine for treating lipometabolism disorder (high blood fat) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1197564C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050457A (en) * | 2012-01-06 | 2017-08-18 | 翁特拉制药公司 | The polyunsaturated fatty acids of Ω 3 of free acid form be rich in DPA compositions |
-
2001
- 2001-09-30 CN CNB011355190A patent/CN1197564C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050457A (en) * | 2012-01-06 | 2017-08-18 | 翁特拉制药公司 | The polyunsaturated fatty acids of Ω 3 of free acid form be rich in DPA compositions |
| US10117844B2 (en) | 2012-01-06 | 2018-11-06 | Omthera Pharmaceuticals, Inc. | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1197564C (en) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1049334C (en) | Fatty acid treatment | |
| Omar et al. | GC-MS analysis of chemical constituents in ethanolic bee pollen extracts from three species of Malaysian stingless bee | |
| CN1224383C (en) | Blood sugar reducing compound | |
| CN107349238A (en) | A kind of auxiliary improvement of memory acer truncatum seed oil compound preparation and its application | |
| CN1197564C (en) | Application of fur seal oil in preparation of medicine for treating lipometabolism disorder (high blood fat) | |
| CN1634033A (en) | Triptolide nano lipsome gelling agent of external use and its preparation method | |
| CN1915986A (en) | High purified tanshinone IIA sodium sulfonate, fabricating method, and preparation | |
| CN1342193A (en) | Method for obtaining oil that rich in hydroxyoctadecadienoic fatty acids (hode) or esters thereof from mixture containing linoleic acid or esters thereof | |
| CN1090490A (en) | The treatment of fatty acid | |
| CN1250230C (en) | Application of fur seal oil in preparation of medicine for treating fatty liver | |
| CN1180783C (en) | Application of fur seal oil in preparation of medicine for treating acute liver damage | |
| CN1180784C (en) | Application of fur seal oil in preparation of medicine for treating prostatauxe | |
| CN1180785C (en) | Application of fur seal oil in preparation of medicine for treating diabetes | |
| CN1286514C (en) | Compound rose essential oil soft capsule and its preparation method | |
| CN1107501C (en) | Albendazole emulsion | |
| CN1954878A (en) | Preparation method of ginger allicin immunity soft capsult | |
| Amantay et al. | Investigation of chemical constituents of Artemisia albicerata | |
| CN1031021A (en) | Cosmetic capable of beautifying women's breasts | |
| CN100340246C (en) | Globefish oil preparation and its preparing method | |
| CN1651407A (en) | Sodium alkyl acyl acetaldehyde sulfite, its synthesis method and use | |
| Nitbani et al. | Green one-step synthesis of 1-monoolein from Kabate larva oil | |
| Ogbuagu et al. | CHROMATOGRAPHIC, INFRARED SPECTRAL AND ANTI-INFLAMMATORY STUDIES OF ETTHYL ACETATE AND METHANOL EXTRACT OF THE SEED OF D. EDULIS | |
| CN1660225A (en) | Medication of effective part of bee pollen form cole, preparation method and application | |
| CN1150915C (en) | Prescription of 'strong heart first-aid dropping pill' and its preparing process | |
| CN1300130C (en) | Rosa banksiae general lactone extract and its preparing process and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHINA BIOCHEMICAL PHARMACEUTICAL INDUSTRY ASSOCIA Free format text: FORMER OWNER: CHINESE VERIFICATION OFFICE OF MEDICINE AND BIOLOGICAL PRODUCTS Effective date: 20070803 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070803 Address after: 100801. Room 45, No. 714, main street, Fuxing gate, Beijing Patentee after: China Biochemical Pharmaceutical Industry Association Address before: No. 2, West Lane, Tiantan, Beijing Patentee before: National Institute for the Control of Pharmaceutical and Biological Products |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050420 Termination date: 20130930 |